ozagrel and Respiratory-Insufficiency

ozagrel has been researched along with Respiratory-Insufficiency* in 3 studies

Other Studies

3 other study(ies) available for ozagrel and Respiratory-Insufficiency

ArticleYear
[The effect of cyclooxygenase and thromboxane synthetase inhibition on oxygen metabolism in canine acute respiratory failure].
    Zhonghua nei ke za zhi, 1993, Volume: 32, Issue:11

    The purpose of this study is to evaluate the effect of cyclooxygenase inhibitor and thromboxane synthetase inhibitor on oxygen metabolism in acute respiratory failure. Acid aspiration was induced in 18 dogs. Six dogs were pretreated with ibuprofen (IBU), six with OKY-046 (OKY), and the remaining six used as control. After acid aspiration oxygen delivery (DO2) fell in all groups as a result of decreased PaO2 and cardiac output. However, oxygen consumption (VO2) was maintained in all animals by the end of the experiment except in the control group. Arterial oxygen content was maintained at baseline level throughout the experiment in IBU group. Meanwhile a significantly decreased mixed venous oxygen tension was found in OKY group after acid challenge. Linear regression of VO2 and DO2 was confirmed in both the control and OKY groups. However, the dependent relationship between VO2 and DO2 was not identified in IBU group; this may indicate that the body oxygen metabolism was maintained rather well in acute respiratory failure dogs treated with ibuprofen.

    Topics: Animals; Cyclooxygenase Inhibitors; Dogs; Ibuprofen; Methacrylates; Oxygen Consumption; Respiratory Insufficiency; Thromboxane-A Synthase

1993
Pulmonary hypertension and leukosequestration after lower torso ischemia.
    Annals of surgery, 1987, Volume: 206, Issue:5

    Ischemia stimulates thromboxane (Tx) synthesis. This study tests the hypothesis that the cardiopulmonary dysfunction that may follow aortic declamping is related to Tx. Anesthetized dogs (N = 15) were subjected to 4 hours of infrarenal aortic cross-clamping. In untreated control animals (N = 7), plasma levels of TxB2 rose from 654 +/- 74 pg/mL to 1238 +/- 585 pg/mL at 5 min (p less than 0.05), and to 3174 +/- 912 pg/mL 3 hours after declamping (p less than 0.05). Mean pulmonary artery pressure (MPAP) rose 5 min after declamping from 13 +/- 2 mmHg to 21 +/- 2 mmHg (p less than 0.05). Cardiac Index (CI) declined during ischemia from 181 +/- 30 mL/kg.min to 128 +/- 16 mL/min.kg (p less than 0.05), and to 80 +/- 8 mL/min.kg after 4 hours of reperfusion (p less than 0.05). Platelet counts declined but platelets labeled with In 111 did not accumulate in the lungs, whereas quantitative counts of polymorphonuclear leukocytes (PMN) in the lungs 4 hours after declamping yielded 213 +/- 33 PMN/25 high power fields (HPF) in dependent areas of the lung and 153 +/- 26 PMN/25 HPF in nondependent areas. The wet/dry weight ratio of the lungs was not elevated, although foci of proteinaceous exudate and PMNs in alveoli were noted. Another group of dogs (N = 8) were pretreated by random choice with the Tx synthase inhibitor OKY-046 2 mg/kg IV every 2 hours, which led to: lower TxB2 levels at baseline 95 +/- 35 pg/mL (p less than 0.05), 5 min after ischemia 140 +/- 93 pg/mL and after 3 hours of reperfusion 122 +/- 36 (p less than 0.05); lower MPAP, 16 +/- 2 mmHg (p less than 0.05); higher CI throughout (p less than 0.05); normal histology and reduced pulmonary PMN sequestration both in dependent 127 +/- 15 PMN/25 HPF and nondependent areas of the lungs 95 +/- 11 PMN/25 HPF (p less than 0.05). In animals undergoing sham ischemia (N = 3), levels of TxB2 and cardiopulmonary function remained unchanged from baseline. There were 150 PMN/25 HPF in dependent and 85 PMN/25 HPF in nondependent lung areas. The results indicate that ischemia-generated Tx mediates a rise in MPAP, a fall in CI, and PMN entrapment in the lungs.

    Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Female; Hypertension, Pulmonary; Ischemia; Leg; Leukocyte Count; Lung; Methacrylates; Neutrophils; Platelet Count; Respiratory Insufficiency; Thromboxane A2; Thromboxane B2; Time Factors

1987
[Protective effect of a thromboxane synthetase inhibitor, OKY-046, in patients with acute respiratory failure].
    Masui. The Japanese journal of anesthesiology, 1984, Volume: 33, Issue:9

    Topics: Acrylates; Acute Disease; Adult; Aged; Female; Humans; Male; Methacrylates; Middle Aged; Oxidoreductases; Respiratory Insufficiency; Thromboxane-A Synthase

1984